Signature Medical is developing AcoustiCare, its flagship wearable product focused on heart failure evaluation and monitoring to improve patient outcomes while preventing hospital re-admissions.
It differs from other typical sensor-based wearables with its proprietary cloud-based audio technology and artificial intelligence enabling remote monitoring and evaluation of heart failure and other indications.
Proceeds from this financing will be used to accelerate the development and commercialization of the AcoustiCare system.
Signature Medical offers innovative solutions focused on value-based healthcare initially focused on heart failure. It is dedicated to improving outcomes while reducing costs in high-value, large underserved markets using proprietary cloud-based and wearable technology.
Riot is an early-stage venture fund that invests in emerging technologies such as artificial intelligence, internet of things, autonomous vehicles, robotics, and augmented and virtual reality. Riot is headquartered in Boston with offices in Los Angeles.
Bose Corp. invests in long-term research with one fundamental goal: to develop new technologies with real customer benefits. Bose innovations have spanned decades and industries, creating and transforming categories in audio and beyond.
FDA grants Priority Review to Genentech's Enspryng for MOGAD
Seismic Pharmaceuticals enrols first patient in istaroxime global Phase 3 trial in cardiogenic shock
BioEdge Research Labs advances transparency in research compound documentation
Insilico Medicine doses first patient in Phase III trial of rentosertib
BridgeBio reports exploratory PROPEL 3 data showing wider clinical trends for oral infigratinib
Tyra Biosciences declares positive Phase 2 results for oral dabogratinib in bladder cancer
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
Kazia Therapeutics doses first patient in paediatric AT/RT study
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Biophytis expands BIO101 obesity study to assess weight regain
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Orphalan commences Phase 3 study of trientine therapy in Wilson disease
ZAGENO named Frost & Sullivan's 2026 North American Life Sciences E-Commerce Company of the Year